Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516

POXEL

(POXEL)
  Report  
Real-time Quote. Real-time CHI-X - 10/16 11:30:00 am
7.67 EUR   -2.79%
10/07POXEL : 3rd quarter earnings
CO
09/18POXEL : Initiates Phase 1b Multiple Ascending Dose Trial for NASH Drug Candidate, PXL065
AQ
08/26POXEL : Half-year results
CO
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results for Imeglimin Phase 3 Trial in Japan for the Treatment of Type 2 Diabetes

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/26/2019 | 10:39am EDT

LYON - POXEL SA (Euronext - POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH) and Sumitomo Dainippon Pharma Co., Ltd (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE), announced today positive top-line Phase 3 data results for the Imeglimin TIMES 3 16-week, double-blind, placebo-controlled, randomized part of the trial for the treatment of type 2 diabetes in Japan.

Referred to as TIMES (Trials of IMeglimin for Efficacy and Safety), the Imeglimin Phase 3 program in Japan includes three pivotal trials to evaluate Imeglimin's efficacy and safety in over 1,100 patients.

'I am very excited to contribute to the development of a new and innovative potential treatment option for Japanese patients with type 2 diabetes,' said Professor Hirotaka Watada, MD, PhD, Professor, Department of Medicine, Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan. 'Imeglimin's safety profile combined with its unique mechanism of action that targets very important deficiencies occurring in diabetes, could be helpful for Japanese patients treated with insulin to further manage their advanced disease.'

The TIMES 3 16-week, double-blind, placebo-controlled, randomized part of the trial evaluated efficacy and safety of Imeglimin in 215 patients. In this trial, Imeglimin 1,000 mg was orally administered twice-daily in combination with insulin in Japanese patients with type 2 diabetes and inadequate glycemic control on insulin therapy versus patients administered placebo and insulin. The TIMES 3 trial was observed to demonstrate efficacy and achieved statistical significance (p

(C) 2019 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
POXEL -1.14% 7.8 Real-time Quote.55.01%
SUMITOMO CHEMICAL COMPANY, LIMITED 0.79% 508 End-of-day quote.-0.59%
SUMITOMO DAINIPPON PHARMA CO., LTD. 1.80% 1813 End-of-day quote.-46.60%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on POXEL
10/07POXEL : 3rd quarter earnings
CO
09/18POXEL : Initiates Phase 1b Multiple Ascending Dose Trial for NASH Drug Candidate..
AQ
08/26POXEL : Half-year results
CO
08/06POXEL : Initiates Pharmacokinetic Pharmacodynamic Study as part of the Phase 2a ..
AQ
07/15GLOBAL MARKETS LIVE : Facebook, Gilead, AB Inbev, Boeing…
07/15POXEL : 2nd quarter earnings
CO
06/26Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results..
AQ
06/25POXEL : and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results ..
PU
04/10Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Im..
AQ
04/08POXEL : Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Tr..
PU
More news
Financials (EUR)
Sales 2019 40,0 M
EBIT 2019 -17,5 M
Net income 2019 -15,1 M
Finance 2019 33,4 M
Yield 2019 -
P/E ratio 2019 -13,3x
P/E ratio 2020 -5,66x
EV / Sales2019 4,27x
EV / Sales2020 7,24x
Capitalization 204 M
Chart POXEL
Duration : Period :
Poxel Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POXEL
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 15,13  €
Last Close Price 7,89  €
Spread / Highest target 115%
Spread / Average Target 91,8%
Spread / Lowest Target 73,6%
EPS Revisions
Managers
NameTitle
Thomas Kuhn Chief Executive Officer & Director
Pierre Legault Chairman
Anne Renevot Chief Financial Officer
Sophie Hallakou-Bozec Senior Vice Chairman-Research & Development
Christophe Arbet-Engels Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
POXEL55.01%225
GILEAD SCIENCES4.40%82 700
VERTEX PHARMACEUTICALS4.76%45 274
REGENERON PHARMACEUTICALS-18.66%33 245
WUXI APPTEC CO., LTD.64.57%20 149
GENMAB30.26%13 356